CMS negotiating prices for sickle cell disease treatment

Having trouble viewing this email? See the online version

Wednesday, January 31, 2024 Wednesday, January 31, 2024 CMS negotiating sickle cell disease treatment prices for states The agency will strike agreements with sickle cell gene therapy manufacturers via the Cell and Gene Therapy Access Model, which it unveiled last February.  Read More > RELATED ARTICLES Blue Cross first to open sickle cell gene therapy floodgates Blues plans launch Synergie to cut costs for the priciest drugs 9 hospitals to offer first FDA-backed sickle cell treatment Leaders like you are also reading Docs see smaller checks as Congress weighs options on Medicare cut Medicare physician reimbursements dipped almost a month ago. A fractious Congress with a packed agenda may or may n... READ MORE > Accompany Health launches with $56M in funding from Venrock, ARCH Accompany provides primary, behavioral and social care to low-income patients through at-home providers and virtual... READ MORE > ProMedica's Paramount Health to be acquired by Medical Mutual ProMedica Health Systems plans to sell its insurance subsidiary Paramount Health to Medical Mutual, a larger insure... READ MORE > Fitch outlines key factors likely to impact providers in 2024 Healthcare leaders must strike a balance between short-term challenges and long-term strategic goals.... READ MORE > UNLOCK YOUR ACCESS Discover the latest news, insight & analysis needed to navigate the healthcare industry. VIEW OUR SUBSCRIPTION OFFERS This email was sent to chunduri22.covid@blogger.com Manage My Account | Contact Us   © 2024 Modern Healthcare 130 E. Randolph St., Suite 3200, Chicago, IL 60601 United States Privacy Policy | Terms and Conditions | Unsubscribe